Effects of azithromycin on serum inflammatory factors and T lymphocyte subsets in patients with gynecological mycoplasma infection.

Abstract

To investigate the effect of azithromycin on the levels of serum inflammatory factors and T lymphocyte subsets in patients with gynecological mycoplasma infection. Records of 250 patients with gynecological mycoplasma infection, treated in our hospital from May 2020 to June 2021, were retrospectively divided into two groups based on the received treatment. Patient (n=120) that were treated with levofloxacin tablets comprised the control group, and patients (n=130) treated with levofloxacin tablets (250mg) and azithromycin tablets comprised the observation group. Changes of serum inflammatory factors and T lymphocyte subsets in the two groups after two weeks of treatment with corresponding drugs were analyzed retrospectively. After the treatment, the levels of C-reactive protein(CRP), interleukin-6(IL-6) and tumor necrosis factor α Tumor necrosis factor α TNF- α in the observation group were significantly lower than those in the control group (P<0.05). Levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were lower than those in the control group (P<0.05). The total clinical efficacy in the observation group was 93.08%, significantly higher than 80.00% in the control group, and the total incidence of adverse drug reactions was 6.15%, significantly lower than 14.17% in the control group (P<0.05). Azithromycin used in clinical treatment of patients with gynecological mycoplasma infection can effectively improve anti-inflammatory and immune response, improve the clinical efficacy of the treatment and reduce adverse reactions.